 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
149 News |  |
| 12» |
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Reduction in the Risk of Peripheral Neuropathy and Preservation of Kidney Function with Metformin, Linagliptin, or Their Fixed-Dose Combination, Compared with Placebo in Prediabetes (Poster Halls B-C; [Board No. 415]) - Apr 10, 2023 - Abstract #ADA2023ADA_2362;
Multicenter, randomized, placebo-controlled trial in 658 individuals aged 45-74 years with prediabetes (IFG or IGT), were randomized to either metformin monotherapy, linagliptin monotherapy, fixed-dose combination of linagliptin/metformin or masked placebo. In people with prediabetes, 1-year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a better preservation of kidney function than with placebo.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
@Boehringer why is Trajenta Duo 2.5/500 out of stock in Indian markets ? (Twitter) - Mar 25, 2023
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - Sep 17, 2021
P=N/A, N=3735, Completed, Sponsor: Boehringer Ingelheim
In people with prediabetes, 1-year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a better preservation of kidney function than with placebo. Active, not recruiting --> Completed
- Onglyza (saxagliptin) / AstraZeneca, Kombiglyze XR (saxagliptin + metformin XR) / AstraZeneca
[VIRTUAL] Incidence of diabetic patients with ASCVD or Heart Failure on DPP4s and candidates for GLP-1 agonists or SGLT-2s for improved cardiovascular outcomes and reduced cost () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4877;
Results are in progress. Will have complete for time of poster presentation.
- Janumet (metformin + sitagliptin) / Merck (MSD), Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
[VIRTUAL] Using diabetes disease state management interventions to improve the patient assistance program application process during a pandemic at a charity clinic () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3591;
Scheduling patients to be seen in DSM and facilitating the application process removes barriers related to adherence and risk of complications. Further follow up can be done to ensure these patients received the benefit of the DSM intervention.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
In #CDMX, Trayenta Duo is out... (Twitter) - Dec 25, 2020
- | metformin / Generic mfg., Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes. (Pubmed Central) - Sep 16, 2020
Further follow up can be done to ensure these patients received the benefit of the DSM intervention. No abstract available
- || metformin / Generic mfg., Glyxambi (empagliflozin / linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. (Pubmed Central) - Aug 4, 2020
The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations. Based on these two bioequivalence studies and existing phase 3 data, the FDA has recently approved this triple FDC to improve glycemic control in adults with T2D.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - May 28, 2020
P=N/A, N=4000, Active, not recruiting, Sponsor: Boehringer Ingelheim
Based on these two bioequivalence studies and existing phase 3 data, the FDA has recently approved this triple FDC to improve glycemic control in adults with T2D. Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: May 2020 --> Jan 2021
- | Review, Journal: Drugs for type 2 diabetes. (Pubmed Central) - Dec 22, 2019
Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: May 2020 --> Jan 2021 No abstract available
- | Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P3 trial: Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (clinicaltrials.gov) - Oct 17, 2019
P3, N=34, Recruiting, Sponsor: Universidad de Guanajuato
- Combination Therapy of Empagliflozin and Linagliptin vs. Metformin and Insulin Glargine on Intra- and Renal Hemodynamics in Type 2 Diabetes (Ballroom C, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5138;
Analysis of intrarenal hemodynamics identified different underlying hemodynamic mechanism, with E+L (surprisingly) mainly decreasing RE and M+I affecting RA. Funding Commercial Support
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin+metformin) / Eli Lilly, Boehringer Ingelheim
Clinical, Journal, Combination therapy, Monotherapy: Which is better, high-dose metformin monotherapy or low-dose metformin/ linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy: A randomized, crossover, CGM-based, pilot study. (Pubmed Central) - Oct 2, 2019
Funding Commercial Support A comparison of GV with HMET versus LMET + DPP4 suggested that LMET + DPP4 might reduce post-breakfast GV to a greater degree than HMET in type 2 diabetes patients receiving low-dose metformin monotherapy.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Enrollment closed, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - Sep 18, 2019
P=N/A, N=4000, Active, not recruiting, Sponsor: Boehringer Ingelheim
A comparison of GV with HMET versus LMET + DPP4 suggested that LMET + DPP4 might reduce post-breakfast GV to a greater degree than HMET in type 2 diabetes patients receiving low-dose metformin monotherapy. Not yet recruiting --> Active, not recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - May 14, 2019
P=N/A, N=4000, Not yet recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Active, not recruiting Trial completion date: Aug 2019 --> May 2020 | Trial primary completion date: Aug 2019 --> May 2020
- | Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, Jentadueto (linagliptin+metformin) / Eli Lilly, Boehringer Ingelheim
Clinical, Journal: Utilising a milk-based meal replacement programme in a bariatric patient with poorly controlled type 2 diabetes mellitus. (Pubmed Central) - Apr 9, 2019
...However, 1 year later, despite further weight loss, his HbA1c deteriorated dramatically, requiring introduction of linagliptin and canagliflozin, with good response...Milk-based meal replacement in patients with insulin requiring type 2 diabetes causes rapid and profound reductions in insulin requirements, so rigorous monitoring of glucose levels by patients and their clinicians is necessary. In carefully selected and adequately monitored patients, the response to oral antidiabetic medications may help to differentiate between absolute and relative insulin deficiency.
- |||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New trial, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - Jan 17, 2019
P, N=4000, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills (clinicaltrials.gov) - Nov 7, 2018
P1, N=30, Completed, Sponsor: Boehringer Ingelheim
In carefully selected and adequately monitored patients, the response to oral antidiabetic medications may help to differentiate between absolute and relative insulin deficiency. Active, not recruiting --> Completed
- || Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment closed: This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills (clinicaltrials.gov) - Sep 26, 2018
P1, N=30, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills (clinicaltrials.gov) - Sep 5, 2018
P1, N=30, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills (clinicaltrials.gov) - Aug 13, 2018
P1, N=30, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood (clinicaltrials.gov) - Nov 17, 2017
P1, N=30, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood (clinicaltrials.gov) - Sep 28, 2017
P1, N=30, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood (clinicaltrials.gov) - Sep 10, 2017
P1, N=30, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood (clinicaltrials.gov) - Aug 22, 2017
P1, N=30, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion, Enrollment change, Trial primary completion date: A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea (clinicaltrials.gov) - Jul 23, 2017
P=N/A, N=724, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Completed | N=600 --> 724 | Trial primary completion date: Sep 2017 --> May 2017
- | Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets (clinicaltrials.gov) - Feb 9, 2017
P1, N=50, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=600 --> 724 | Trial primary completion date: Sep 2017 --> May 2017 Active, not recruiting --> Completed
- | metformin / Generic mfg., Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Journal: Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. (Pubmed Central) - Feb 7, 2017
P4
Linagliptin/metformin combination in newly diagnosed T2D patients with marked hyperglycemia was well tolerated and elicited substantial improvements in glycemic control regardless of baseline HbA1c, age, BMI, renal function, or race. Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents.
- Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets (clinicaltrials.gov) - Aug 29, 2016
P1, N=50, Active, not recruiting, Sponsor: Boehringer Ingelheim
Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents. Recruiting --> Active, not recruiting
- Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets (clinicaltrials.gov) - Aug 2, 2016
P1, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Trijardy XR (empagliflozin/linagliptin/metformin XR) / Eli Lilly, Boehringer Ingelheim, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets (clinicaltrials.gov) - Jul 5, 2016
P1, N=50, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P3 trial: Early Prevention of Diabetes Complications in people with Pre-Diabetes in Europe Prevenci (EUDRACT) - Dec 19, 2014
P3, N=3000, Ongoing, Sponsor: FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects (clinicaltrials.gov) - Aug 22, 2014
P1, N=32, Completed, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=96, Completed, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=95, Completed, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=96, Completed, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Aug 7, 2014
P1, N=74, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Aug 7, 2014
P1, N=68, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. (clinicaltrials.gov) - Jul 24, 2014
P1, N=74, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment closed: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Jun 27, 2014
P1, N=68, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects (clinicaltrials.gov) - Jun 26, 2014
P1, N=20, Completed, Sponsor: Boehringer Ingelheim
- || Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment closed: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Jun 26, 2014
P1, N=74, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment closed: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. (clinicaltrials.gov) - Jun 13, 2014
P1, N=74, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - May 18, 2014
P1, N=74, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: CAROLINA: Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug na (clinicaltrials.gov) - May 12, 2014
P3, N=876, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Completed --> Recruiting
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. (clinicaltrials.gov) - Apr 29, 2014
P1, N=74, Recruiting, Sponsor: Boehringer Ingelheim
Completed --> Recruiting Not yet recruiting --> Recruiting
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Apr 21, 2014
P1, N=74, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Enrollment open: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Apr 15, 2014
P1, N=68, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects (clinicaltrials.gov) - Mar 9, 2014
P1, N=68, Recruiting, Sponsor: Boehringer Ingelheim
- ||| Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P1 trial: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. (clinicaltrials.gov) - Mar 9, 2014
P1, N=74, Recruiting, Sponsor: Boehringer Ingelheim